Financial reports
10-Q
2008 Q1
Quarterly report
12 May 08
ARS
2007 FY
Annual report to shareholders
11 Apr 08
10-K
2007 FY
Annual report
29 Feb 08
10-Q
2007 Q3
Quarterly report
9 Nov 07
10-Q
2007 Q2
Quarterly report
8 Aug 07
10-Q
2007 Q1
Quarterly report
9 May 07
10-K
2006 FY
Annual report
1 Mar 07
10-Q
2006 Q3
Quarterly report
31 Oct 06
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 May 08
8-K
Departure of Directors or Principal Officers
15 Apr 08
8-K
Millennium Announces Velcade® (Bortezomib) for Injection First-quarter 2008 U.s. Net Sales
10 Apr 08
8-K
Takeda to Acquire Millennium for US$25.00 Per Share In an All Cash Tender Offer Valued at $8.8 Billion
10 Apr 08
8-K
Regulation FD Disclosure
29 Feb 08
8-K
Results of Operations and Financial Condition
7 Feb 08
8-K
Results of Operations and Financial Condition
4 Jan 08
8-K
Millennium Reports Outstanding Third-quarter Results Driven by Velcade® (Bortezomib) for Injection Sales
1 Nov 07
8-K
Departure of Directors or Principal Officers
5 Oct 07
8-K
Millennium Highlights Strong Second-quarter Results and Upcoming Growth Catalysts
26 Jul 07
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
POS AM
Prospectus update (post-effective amendment)
6 Jun 08
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jun 08
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Jun 08
Proxies
DEF 14A
Definitive proxy
7 Apr 08
DEFA14A
Additional proxy soliciting materials
7 Apr 08
DEF 14A
Definitive proxy
28 Mar 07
PRE 14A
Preliminary proxy
12 Mar 07
DEF 14A
Definitive proxy
22 Mar 06
DEF 14A
Definitive proxy
22 Mar 05
DEF 14A
Definitive proxy
24 Mar 04
DEF 14A
Definitive proxy
18 Mar 03
DEF 14A
Definitive proxy
12 Mar 02
DEF 14A
Definitive proxy
23 Mar 01
Other
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
EFFECT
Notice of effectiveness
9 Jun 08
UPLOAD
Letter from SEC
17 Jan 08
CORRESP
Correspondence with SEC
11 Jan 08
Ownership
3
Calithera Biosciences, Inc.
21 Apr 22
4
Day One Biopharmaceuticals, Inc.
9 Dec 21
4
Day One Biopharmaceuticals, Inc.
7 Dec 21
4
Day One Biopharmaceuticals, Inc.
29 Nov 21
3
Day One Biopharmaceuticals, Inc.
26 May 21
4
Ovid Therapeutics Inc.
22 Nov 19
3
Ovid Therapeutics Inc.
22 Nov 19
3
Myovant Sciences Ltd.
29 Mar 18
SC 13G
Myovant Sciences Ltd.
29 Mar 18
3
A/S Takeda
8 Sep 17